JP2008539258A - タナプロゲットの精製形態ii - Google Patents

タナプロゲットの精製形態ii Download PDF

Info

Publication number
JP2008539258A
JP2008539258A JP2008509091A JP2008509091A JP2008539258A JP 2008539258 A JP2008539258 A JP 2008539258A JP 2008509091 A JP2008509091 A JP 2008509091A JP 2008509091 A JP2008509091 A JP 2008509091A JP 2008539258 A JP2008539258 A JP 2008539258A
Authority
JP
Japan
Prior art keywords
tanaproget
polymorph
solution
water
concentrated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008509091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008539258A5 (cg-RX-API-DMAC7.html
Inventor
テスコニ,マーク,サドラー
クー,マンチン,シェリー
シュ,ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of JP2008539258A publication Critical patent/JP2008539258A/ja
Publication of JP2008539258A5 publication Critical patent/JP2008539258A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2008509091A 2005-04-28 2006-04-26 タナプロゲットの精製形態ii Pending JP2008539258A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67573705P 2005-04-28 2005-04-28
PCT/US2006/015852 WO2006116526A2 (en) 2005-04-28 2006-04-26 Polymorph form ii of tanaproget

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013242731A Division JP2014088385A (ja) 2005-04-28 2013-11-25 タナプロゲットの精製形態ii

Publications (2)

Publication Number Publication Date
JP2008539258A true JP2008539258A (ja) 2008-11-13
JP2008539258A5 JP2008539258A5 (cg-RX-API-DMAC7.html) 2009-06-04

Family

ID=36954854

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008509091A Pending JP2008539258A (ja) 2005-04-28 2006-04-26 タナプロゲットの精製形態ii
JP2013242731A Pending JP2014088385A (ja) 2005-04-28 2013-11-25 タナプロゲットの精製形態ii

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013242731A Pending JP2014088385A (ja) 2005-04-28 2013-11-25 タナプロゲットの精製形態ii

Country Status (11)

Country Link
US (4) US7759341B2 (cg-RX-API-DMAC7.html)
EP (1) EP1874763A2 (cg-RX-API-DMAC7.html)
JP (2) JP2008539258A (cg-RX-API-DMAC7.html)
CN (1) CN101166736B (cg-RX-API-DMAC7.html)
AR (1) AR053596A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006241125B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0610433A2 (cg-RX-API-DMAC7.html)
CA (1) CA2603807A1 (cg-RX-API-DMAC7.html)
MX (1) MX2007013469A (cg-RX-API-DMAC7.html)
TW (1) TW200716621A (cg-RX-API-DMAC7.html)
WO (1) WO2006116526A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539262A (ja) * 2005-04-28 2008-11-13 ワイス ミクロ化タナプロゲットおよびこれを含む組成物
JP2008539264A (ja) * 2005-04-28 2008-11-13 ワイス ミクロ化タナプロゲットを含む組成物
JP2008539256A (ja) * 2005-04-28 2008-11-13 ワイス ミクロ化タナプロゲット、組成物およびその調製方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
MX2007013469A (es) * 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
MX2007015571A (es) 2005-06-09 2008-03-06 Wyeth Corp Composiciones de tanaproget que contienen etinilestradiol.
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
US20110237605A1 (en) * 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
EP2877465A4 (en) 2012-07-25 2016-05-11 Sarcode Bioscience Inc LFA-1 HEMMER AND POLYMORPH THEREOF
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543192A (ja) * 1999-05-04 2002-12-17 ワイス プロゲステロン受容体モジュレーターとしてのシクロチオカルバメート誘導体
US20050053639A1 (en) * 2003-06-26 2005-03-10 Shalaby Shalaby W Partially absorbable fiber-reinforced composites for controlled drug delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
EP1531824A4 (en) * 2002-06-25 2005-09-21 Wyeth Corp CYCLOTHIOCARBAMATE DERIVATIVES AS PR-MODULATORS AND THEIR USE IN THE TREATMENT OF SKIN DISEASES
AU2003247608A1 (en) * 2002-06-25 2004-01-06 Wyeth Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
BRPI0510260A (pt) 2004-04-27 2007-10-23 Wyeth Corp método para purificar um composto, e, kit farmacêutico
PA8631101A1 (es) 2004-04-27 2006-09-08 Wyeth Corp Proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos
AU2005272854B2 (en) * 2004-08-13 2012-04-26 Wyeth Tanaproget derivatives, metabolites, and uses thereof
BRPI0610438A2 (pt) 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, cápsula, conjunto farmacêutico, e, processo para preparar uma composição
ES2431324T3 (es) 2005-04-28 2013-11-26 Wyeth Llc Forma purificada de tanaproget
WO2006116596A2 (en) 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compostions containing same
US7767668B2 (en) 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
MX2007013469A (es) 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
MX2007015571A (es) 2005-06-09 2008-03-06 Wyeth Corp Composiciones de tanaproget que contienen etinilestradiol.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543192A (ja) * 1999-05-04 2002-12-17 ワイス プロゲステロン受容体モジュレーターとしてのシクロチオカルバメート誘導体
US20050053639A1 (en) * 2003-06-26 2005-03-10 Shalaby Shalaby W Partially absorbable fiber-reinforced composites for controlled drug delivery

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
実験化学講座(続)2 分離と精製, JPN6012022299, 25 January 1967 (1967-01-25), pages 159 - 78, ISSN: 0002584948 *
新・薬剤学総論(改訂第3版), vol. 株式会社南江堂, JPN6012025458, 10 April 1987 (1987-04-10), pages 111, ISSN: 0002584947 *
新製剤学, JPN6012022297, 25 April 1984 (1984-04-25), pages 102 - 103, ISSN: 0002214028 *
調剤学−基礎と応用−, JPN6012022295, 20 September 1977 (1977-09-20), pages 142 - 145, ISSN: 0002214027 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539262A (ja) * 2005-04-28 2008-11-13 ワイス ミクロ化タナプロゲットおよびこれを含む組成物
JP2008539264A (ja) * 2005-04-28 2008-11-13 ワイス ミクロ化タナプロゲットを含む組成物
JP2008539256A (ja) * 2005-04-28 2008-11-13 ワイス ミクロ化タナプロゲット、組成物およびその調製方法
JP2012255000A (ja) * 2005-04-28 2012-12-27 Wyeth Llc ミクロ化タナプロゲットおよびこれを含む組成物
JP2012254999A (ja) * 2005-04-28 2012-12-27 Wyeth Llc ミクロ化タナプロゲットを含む組成物
US8343965B2 (en) 2005-04-28 2013-01-01 Wyeth Llc Compositions containing micronized tanaproget prepared by wet granulation
JP2013006840A (ja) * 2005-04-28 2013-01-10 Wyeth Llc ミクロ化タナプロゲット、組成物およびその調製方法
US8450312B2 (en) 2005-04-28 2013-05-28 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
US8513240B2 (en) 2005-04-28 2013-08-20 Wyeth Llc Micronized tanaproget and compositions containing same
US8772271B2 (en) 2005-04-28 2014-07-08 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
US8791109B2 (en) 2005-04-28 2014-07-29 Wyeth Llc Compositions containing micronized tanaproget prepared by wet granulation
JP2014205683A (ja) * 2005-04-28 2014-10-30 ワイス・エルエルシー ミクロ化タナプロゲットを含む組成物
JP2014205684A (ja) * 2005-04-28 2014-10-30 ワイス・エルエルシー ミクロ化タナプロゲットおよびこれを含む組成物

Also Published As

Publication number Publication date
JP2014088385A (ja) 2014-05-15
US8114869B2 (en) 2012-02-14
WO2006116526A8 (en) 2007-08-16
US7968709B2 (en) 2011-06-28
AU2006241125B2 (en) 2012-07-05
US7759341B2 (en) 2010-07-20
WO2006116526A3 (en) 2007-06-28
CN101166736A (zh) 2008-04-23
US20060247235A1 (en) 2006-11-02
AR053596A1 (es) 2007-05-09
US20100267715A1 (en) 2010-10-21
BRPI0610433A2 (pt) 2010-11-23
EP1874763A2 (en) 2008-01-09
US20120115858A1 (en) 2012-05-10
TW200716621A (en) 2007-05-01
WO2006116526A2 (en) 2006-11-02
US20110212953A1 (en) 2011-09-01
AU2006241125A1 (en) 2006-11-02
CN101166736B (zh) 2013-02-06
CA2603807A1 (en) 2006-11-02
MX2007013469A (es) 2008-01-22

Similar Documents

Publication Publication Date Title
US7968709B2 (en) Process for preparing polymorph form II of tanaproget
JP2013231042A (ja) タナプロゲットの精製形態
US8791109B2 (en) Compositions containing micronized tanaproget prepared by wet granulation
US20080249148A1 (en) Synthesis and characterization of polymorph form III 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
US20080234340A1 (en) Synthesis and characterization of polymorph form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-YL)thiazol-4-YL)benzonitrile
US20080312306A1 (en) Polymorphs, solvates, and hydrate of 5-(4'-fluoro-2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'-yl)-1-methyl-1h-pyrrole-2-carbonitrile

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120801

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131224

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140702

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20141205